<DOC>
	<DOCNO>NCT00230230</DOCNO>
	<brief_summary>This randomize , multicenter , parallel-group , double-blind , double-dummy , placebo- active-controlled study evaluate efficacy safety SCH 486757 subject persistent cough result recent viral upper respiratory infection ( URI ) . The primary objective ass efficacy SCH 486757 administer dose 100 mg twice daily 5 day reduction cough severity score compare placebo . The key secondary objective evaluate reduction number cough SCH 486757 compare placebo . Because codeine widely use cough medication , include treatment arm study .</brief_summary>
	<brief_title>Comparison SCH 486757 Codeine Placebo Subjects With Persistent Postviral Cough ( Study P03069AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<mesh_term>Codeine</mesh_term>
	<criteria>Subjects must 18 &lt; 65 year age , either sex , race . At prescreening visit ( Visit 1 ) , subject must history persistent cough result recent viral URI . Subjects must sufficiently clinically symptomatic screen visit ( Visit 2 ) . At Baseline/Treatment Day 1 Visit ( Visit 3 ) , subject must demonstrate average cough severity score least 2 ( moderate ) . Subjects must good health , free clinically significant disease , cough , might interfere study schedule , evaluation , interpretation studyderived data . Subjects must willing give write informed consent able adhere dose visit schedule . Clinical laboratory test ( complete blood count , blood chemistry , urinalysis ) electrocardiograms must within normal limit clinically acceptable investigator . Female subject childbearing potential must use medically accept method birth control . Female subject childbearing potential must negative serum pregnancy test ( betahCG ) ( prescreening sample ) . Subjects pregnant nursing female . Subjects history hypersensitivity study medication excipients . Subjects use study medication , include placebo , investigational protocol within 30 day prior prescreening visit ( Visit 1 ) . Subjects receive concurrent prohibit medication , unless observe washout period prior screen baseline visit ( Visits 2 3 ) . Subjects family member investigational study staff involve study . Subjects previously enrol study ( ie , sign informed consent ) . Subjects current evidence clinically significant pulmonary ( especially condition involve cough ) , hematopoietic , cardiovascular , hepatic , renal , neurologic , psychiatric , autoimmune , disease precludes subject 's participation study . In particular , diabetic , uncontrolled hypertensive , subject clinically significant cardiomyopathy , prostatic hypertrophy , glaucoma , psychiatric disorder exclude participation study . Particular attention give exclude subject condition would currently interfere absorption , distribution , metabolism , excretion study medication interfere subject 's ability reliably complete diary card . Subjects asthma chronic obstructive pulmonary disease require chronic use inhale systemic corticosteroid . Subjects current history frequent clinically significant sinusitis chronic purulent postnasal drip . Subjects history allergy two class medication . Subjects whose ability , opinion investigator designee , provide informed consent compromise . Subjects history noncompliance medication treatment protocol , history drug abuse . Current smoker , exsmokers stop smoke previous 6 month , subject cumulative smoke history &gt; 10 packyears exclude . ( Packyears way measure amount person smoke long period time . It calculate multiply number pack cigarettes smoked per day number year person smoke , eg , 10 packyear history equal smoking 1 pack per day 10 year 2 pack per day 5 year , etc . ) Subjects current reflux disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>